发布时间 :2016-12-07  阅读次数 :2926

报告题目:Embryonic and cancer stem cells

报  告 人: Lisheng Wang, Ph.D., University of Ottawa Ottawa

报告时间: 12月09日15:00

报告地点: 闵行校区文选医学大楼217室

联  系 人: 徐汪节 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.


Dr Wang is Associate Professor of Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa. He obtained his BSc in Medicine at Shanxi Medical University (Taiyuan, China), MSc in Internal Medicine at Shanghai Medical University (Shanghai, China) and PhD in Transplantation Immunology at Sydney University (Sydney, Australia). Dr. Wang then pursued postdoctoral research in Immunology at Harvard Medical School (Boston, USA) and further postdoctoral research in Stem Cell Biology and Regenerative Medicine at Robarts Research Institute (London, Canada). Dr Wang was appointed as Assistant Professor (tenure track) in 2005 and Associated Professor (tenured) in 2011 at Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa. Using cellular and molecular approaches and in vivo animal models, Dr. Wang’s laboratory is interested in: (1) nurturing human embryonic stem cells into mothers of circulatory cells for stem cell-based therapy; (2) targeting embryonic signaling pathways in cancer for more effective treatment. His lab’s research is supported by Canadian Institutes of Health Research, Canadian Breast Cancer Foundation, Canadian Foundation for Innovation, and other funds. His lab’s most recent publications have demonstrated that a regulatory network involving β-catenin, E-cadherin, PI3K/Akt, and Slug balances self-renewal and differentiation of human pluripotent stem cells in response to Wnt signaling; milk fat globule epidermal growth factor 8 is critical for embryonic stem cell-mediated T cell immunomodulation and immune acceptance. Dr. Wang’s lab has also found that dual inhibition of Wnt/β-catenin and NF-κB signaling and/or other pathways are effective approaches for targeting both bulk and cancer stem cell populations. Considerable papers published by Dr. Wang and his group have been highly cited or highlighted by the journals. He has received national awards for his excellent research.